New Analysis Shows STELARA(R) Efficacy Consistent in Asian vs. US and European PatientsBy Janssen Asia Pacific, PRNE
Thursday, May 26, 2011
SEOUL, South Korea, May 27, 2011 -
- This Media Alert is Intended for Hong Kong, New Zealand, The
Philippines, Singapore and Thailand Only
- Data Presented at World Congress of Dermatology
Results presented at the World Congress of Dermatology (WCD) show the
efficacy and safety of STELARA(R) in psoriasis patients of Japanese, Korean
and Taiwanese descent were consistent with those reported in North American
and European populations.
Psoriasis, a chronic, immune-mediated disease that results from the
overproduction of skin cells, affects 125 million people worldwide. The
disease symptoms can range from mild, to moderate, to severe and disabling.
"Psoriasis affects millions of people in Asia and these findings show
that STELARA can provide Asian patients with significant improvements in
their condition, consistent with improvements in patients of European
ethnicity," said Dr Alexander Rodríguez Morales MD, Asia Pacific Medical
Affairs Associate Director for Janssen.
STELARA efficacy and safety was analysed in patients with moderate to
severe plaque psoriasis across four placebo-controlled Phase 3 trials through
28 Weeks. Japanese, Korean and Taiwanese populations evaluated in the JPN-02
(n=158) and PEARL (n=121) trials, respectively, were compared with European
and US patients populations in PHOENIX 1 (n=766) and PHOENIX 2 (n=1230).
STELARA treatment demonstrated similar efficacy in Asian and non-Asian
moderate-to-severe psoriasis populations through Week 28 across trials,
showing consistency of response among different ethnic populations.
STELARA treatment at Weeks 0 and 4 led to significant improvement in
moderate-to-severe psoriasis at Week 12 in both Asian and non-Asian
PASI 75 (Psoriasis Area and Severity Index) responses and PGA
(Physician's Global Assessment) improvements achieved at Week 12 were
generally maintained through Week 28 across trials.
Dermatology Life Quality Index (DLQI) scores in STELARA patients showed
clinically meaningful improvements compared to the placebo patients across
The analysis also found STELARA was well-tolerated among Asian and
non-Asian populations and adverse event rates were similar between the
placebo and STELARA groups through Week 28.
This analysis is one of a number of studies on the treatment of psoriasis
with STELARA being announced at WCD this week.
More information on STELARA can be found at www.stelarainfo.com or
Important Safety Information
STELARA is a prescription medicine that affects your immune system.
STELARA can increase your chance of having serious side effects including:
STELARA may lower your ability to fight infections and may increase your
risk of infections. While taking STELARA, some people have serious
infections, which may require hospitalization, including tuberculosis (TB),
and infections caused by bacteria, fungi, or viruses.
- Your doctor should check you for TB before starting STELARA and watch
you closely for signs and symptoms of TB during treatment with STELARA.
- If your doctor feels that you are at risk for TB, you may be treated
for TB before and during treatment with STELARA.
You should not start taking STELARA if you have any kind of infection
unless your doctor says it is okay.
Before starting STELARA, tell your doctor if you think you have an
infection or have symptoms of an infection such as:
- fever, sweats, or chills
- muscle aches
- shortness of breath
- blood in your phlegm
- weight loss
- warm, red, or painful skin or sores on your body
- diarrhea or stomach pain
- burning when you urinate or urinate more often than normal
- feel very tired
- are being treated for an infection
- get a lot of infections or have infections that keep coming back
- have TB, or have been in close contact with someone who has TB
After starting STELARA, call your doctor right away if you have any
symptoms of an infection (see above).
STELARA can make you more likely to get infections or make an infection
that you have worse. People who have a genetic problem where the body does
not make any of the proteins interleukin 12 (IL-12) and interleukin 23
(IL-23) are at a higher risk for certain serious infections that can spread
throughout the body and cause death. It is not known if people who take
STELARA will get any of these infections because of the effects of STELARA on
STELARA may decrease the activity of your immune system and increase your
risk for certain types of cancer. Tell your doctor if you have ever had any
type of cancer.
Reversible posterior leukoencephalopathy syndrome (RPLS)
RPLS is a rare condition that affects the brain and can cause death. The
cause of RPLS is not known. If RPLS is found early and treated, most people
recover. Tell your doctor right away if you have any new or worsening medical
problems including: headache, seizures, confusion, and vision problems.
Serious Allergic Reactions
Serious allergic reactions can occur. Get medical help right away if you
have any symptoms such as: feeling faint, swelling of your face, eyelids,
tongue, or throat, trouble breathing, throat or chest tightness, or skin
Before receiving STELARA, tell your doctor if you:
- have any of the conditions or symptoms listed above for
serious infections, cancer, or RPLS
- have recently received or are scheduled to receive an
immunization (vaccine). People who take STELARA should not receive live
vaccines. Tell your doctor if anyone in your house needs a vaccine. The
viruses used in some types of vaccines can spread to people with a
weakened immune system, and can cause serious problems. You should not
receive the BCG vaccine during the one year before taking STELARA or one
year after you stop taking STELARA. Non-live vaccinations received while
taking STELARA may not fully protect you from disease.
- are receiving or have received allergy shots, especially for
serious allergic reactions.
- ever had an allergic reaction to STELARA.
- receive phototherapy for your psoriasis.
- have any other medical conditions.
- are pregnant or plan to become pregnant. It is not known if STELARA
will harm your unborn baby. You and your doctor should decide if you will
- are breast-feeding or plan to breast-feed. It is thought that STELARA
passes into your breast milk. You should not breast-feed while taking STELARA
without first talking to your doctor.
Tell your doctor about all the medicines you take, including prescription
and non-prescription medicines, vitamins, and herbal supplements. Especially
tell your doctor if you take:
- other medicines that affect your immune system
- certain medicines that can affect how your liver breaks down other
Common side effects of STELARA include: upper respiratory infections,
headache, and tiredness. These are not all of the side effects with STELARA.
Tell your doctor about any side effect that bothers you or does not go away.
Ask your doctor or pharmacist for more information.
 Youn J, et al. Consistency of responses across different ethnic
populations with moderate-to-severe psoriasis: Results from the ustekinumab
psoriasis clinical development program. Proceedings of the 22nd World
Congress of Dermatology; 2011 May 29-29; Seoul, Korea. P2504
For more information contact: Ruth Fazakerley, Janssen Asia Pacific,
Tags: Janssen Asia Pacific, May 27, Seoul, South Korea